Page contentsPage contents Key facts Decision Key facts Active substance Ibrexafungerp Therapeutic area Infections and infestations Decision number EMA/PE/0000225106 PIP number EMA/PE/0000225106 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Prevention of recurrent vulvovaginal candidiasisTreatment of vulvovaginal candidiasis Route(s) of administration Oral use Contact for public enquiries Glaxosmithkline Trading Services LimitedE-mail: info@scynexis.comTel: +1(201)8845485 Decision type PM: decision on the application for modification of an agreed PIP Decision date 25/10/2024 Compliance check done No Decision EMA/PE/0000225106: EMA decision of 25 October 2024 on the acceptance of a modification of an agreed paediatric investigation plan for ibrexafungerpAdopted Reference Number: EMADOC-1700519818-1723829 English (EN) (220.11 KB - PDF)First published: 23/10/2025 View Share this page